» Articles » PMID: 9469390

Epidemiology of Invasive Pneumococcal Disease in the Western Region, The Gambia

Overview
Specialty Pediatrics
Date 1998 Feb 20
PMID 9469390
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Streptococcus pneumoniae is a major cause of morbidity and mortality in young children in the developing world. The recent development of pneumococcal polysaccharide/protein conjugate vaccines may make possible prevention of this infection. However, little is known about the epidemiology of invasive pneumococcal disease in children in the developing world.

Objectives: To determine the incidence and epidemiologic features of invasive pneumococcal disease in children resident in a semiurban area of The Gambia.

Method: The study was part of a large trial of an Haemophilus influenzae type b vaccine that recruited 42 848 children at the age of 2 months during the period March, 1993, to October, 1995. Follow-up of study children continued until December 31, 1995; therefore the first children to enter the trial were followed for 2.5 years and the last for just a few months. During the period of surveillance, 2256 children were investigated for possible invasive pneumococcal disease when they presented to a hospital or health center.

Results: We detected 110 cases of pneumococcal disease. Pneumonia was the most common form of invasive pneumococcal disease observed (75.5% of patients). The incidence of pneumococcal disease was 224 [95% confidence interval (CI) 171, 277] per 100,000 child years among children ages 2 to 11 months, 139 (95% CI 93, 184) per 100,000 among children ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among children ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19, 46 and 2 were isolated most frequently. Susceptibility to pneumococcal disease was not increased significantly among Haemophilus influenzae type b-vaccinated children.

Conclusions: The pneumococcus is a major cause of bacterial infection in The Gambia. A proposed nine-valent pneumococcal conjugate vaccine for developing countries containing conjugates of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74% of cases of invasive pneumococcal disease in children resident in the Western Region of The Gambia.

Citing Articles

Population-based incidence and serotype distribution of invasive pneumococcal disease prior to introduction of conjugate pneumococcal vaccine in Bangladesh.

Baqui A, McCollum E, Mahmud A, Roy A, Chowdhury N, Rafiqullah I PLoS One. 2020; 15(2):e0228799.

PMID: 32053640 PMC: 7018078. DOI: 10.1371/journal.pone.0228799.


Genetic Determinants of Tetracycline Resistance in Clinical Streptococcus pneumoniae Serotype 1 Isolates from Niger.

Ousmane S, Diallo B, Ouedraogo R Antibiotics (Basel). 2018; 7(1).

PMID: 29509667 PMC: 5872130. DOI: 10.3390/antibiotics7010019.


Burden of invasive pneumococcal disease among children in rural Mozambique: 2001-2012.

Sigauque B, Verani J, Massora S, Vubil D, Quinto L, Acacio S PLoS One. 2018; 13(1):e0190687.

PMID: 29304066 PMC: 5755904. DOI: 10.1371/journal.pone.0190687.


Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.

DeAntonio R, Yarzabal J, Cruz J, Schmidt J, Kleijnen J Hum Vaccin Immunother. 2016; 12(9):2422-40.

PMID: 27269963 PMC: 5027706. DOI: 10.1080/21645515.2016.1174356.


Population structure, epidemiology and antibiotic resistance patterns of Streptococcus pneumoniae serotype 5: prior to PCV-13 vaccine introduction in Eastern Gambia.

Ashu E, Jarju S, Dione M, Mackenzie G, Ikumapayi U, Manjang A BMC Infect Dis. 2016; 16:33.

PMID: 26822883 PMC: 4731921. DOI: 10.1186/s12879-016-1370-0.